Alkermes Plc (ALKS.O)
22 Aug 2014
|Market Cap (Mil.):||$6,305.60|
|Shares Outstanding (Mil.):||145.83|
SAN DIEGO - Dublin, Ireland-based Alkermes Plc has the low-tax domicile currently in vogue among multinational pharmaceutical companies but is not interested in being bought out as it nears the launch of new drugs, its chief executive said on Monday.
- Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent.
* To apply for U.S. marketing approval in the third quarter
(Corrects to remove paragraphs referring to Alzheimer's disease. Alkermes' drug is not used to treat Alzheimer's)
April 8 - Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study.
|Novo Nordisk A/S (NOVOb.CO)||kr.254.20||-2.10|
|Novartis AG (NOVN.VX)||CHF81.35||+0.25|
|Bayer AG (BAYGn.DE)||€95.41||-2.28|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€79.43||-1.16|
|Eli Lilly and Co (LLY.N)||$62.32||+0.29|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||19,070.00₪||+410.00|
|Merck KGaA (MRCG.DE)||€63.00||-1.90|
|Biogen Idec Inc (BIIB.OQ)||$339.97||+1.32|
|Forest Laboratories, Inc. (FRX.N)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Pechala's Reports
Alkermes Plc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Ford Investor Services, Inc.
"The Economy Matters" Report for ALKS: the economy's impact on ALKS's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.